Company intelligence / Profile preview

Polaris Therapeutics

Taipei, Zhunan, Tainan, Taiwan

Ownership: Private
Employees: ~160
Development stage: Other

Overview

ADI-PEG 20 is in Phase III trials for three cancer indications, with BLA filing completed for malignant pleural mesothelioma; semaglutide peptide product is expected to commence large-scale production and commercialization in the coming year.

Therapeutic areas: OncologyEndocrinology
Modalities: Small moleculePeptideBiologic
Industry: Biotech

Partnerships

Negotiations underway with global/regional commercialization partners for anti-cancer drugs; specific partners not named

Beyond the preview

Go deeper on Polaris Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polaris Therapeutics.

Explore the full profile